Hualin Lüthi, Sophia Lengsfeld, Thilo Burkard, Andrea Meienberg, Nica Jeanloz, Tanja Vukajlovic, Katja Bologna, Michelle Steinmetz, Cemile Bathelt, Clara O Sailer, Mirjam Laager, Deborah R Vogt, Lars G Hemkens, Benjamin Speich, Sandrine A Urwyler, Jill Kühne, Fabienne Baur, Linda N Lutz, Tobias E Erlanger, Mirjam Christ-Crain, Bettina Winzeler
BACKGROUND: Smoking cessation is challenging, despite making use of established smoking cessation therapies. Preclinical studies and one clinical pilot study suggest the antidiabetic drug glucagon-like peptide-1 (GLP-1) analogue to modulate addictive behaviours and nicotine craving. Previously, we reported the short-term results of a randomised, double-blind, placebo-controlled trial. Herein we report long-term abstinence rates and weight developments after 24 and 52 weeks. METHODS: This single-centre, randomised, double-blind, placebo-controlled, parallel group trial was done at the University Hospital Basel in Switzerland...
February 2024: EClinicalMedicine